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Diacylglycerol Kinase Regulates Tyrosinase
Expression and Function in Human Melanocytes
Masakazu Kawaguchi1, Julio C. Valencia1, Takeshi Namiki1, Tamio Suzuki2 and Vincent J. Hearing1
Diacylglycerol (DAG) increases the melanin content of human melanocytes in vitro and increases the
pigmentation of guinea pig skin in vivo, but the mechanism(s) underlying those effects remain unknown. In this
study, we characterized the role of diacylglycerol kinase (DGK), which phosphorylates DAG to generate
phosphatidic acid, in the regulation of pigmentation. Ten isoforms of DGK have been identified, and we show
that DGKz is the most abundant isoform expressed by human melanocytic cells. Melanin content, tyrosinase
activity, and tyrosinase protein levels were significantly reduced by a DGK inhibitor, but tyrosinase and
microphthalmia-associated transcription factor messenger RNA (mRNA) levels were not changed by that
inhibition, and there were no effects on the expression of other melanogenesis-related proteins. Isoform-
specific small interfering RNAs showed that knockdown of DGKz decreased melanin content and tyrosinase
expression in melanocytic cells. Overexpression of DGKz increased tyrosinase protein levels, but did not
increase tyrosinase mRNA levels. Glycosidase digestion revealed that inhibition of DGK reduced only the
mature form of tyrosinase, and the decrease of tyrosinase resulting from DGK inhibition could be blocked
partially by protease inhibitors. These results suggest that DGK regulates melanogenesis via modulation of the
posttranslational processing of tyrosinase, which may be related with the protein degradation machinery.
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INTRODUCTION
Many hormones, growth factors, and other cell stimuli evoke a
transient increase in the levels of cellular diacylglycerol (DAG)
through hydrolysis of phosphoinositides by phospholipase C
(reviewed in (Sakane et al., 2007, 2008)). A possible role for
DAG in regulating human pigmentation was first reported in a
study that showed that DAG increases the melanin content of
human melanocytes in culture (Gordon and Gilchrest, 1989).
The melanin content induced by DAG could be completely
blocked by a protein kinase C (PKC) inhibitor. It has been
reported that topical application of DAG increases pigmenta-
tion in guinea pig skin in a dose-dependent manner (Allan
et al., 1995). Ultraviolet radiation induces the formation of
DAG in human melanocytes, (Carsberg et al., 1995) and
therefore DAG is considered to be an important factor that
may regulate melanogenesis in the skin.
To date, 10 isoforms of diacylglycerol kinase (DGK) have
been identified and characterized in mammals. DGK
phosphorylates DAG to generate phosphatidic acid (PA).
DAG and PA are second messengers, which are involved in
several major intracellular signal transduction pathways.
DGKs differ in their activators, expression patterns, substrate
specificities, and structural domains. DGKs can be divided
into five subfamilies according to their distinctive structural
motifs and functions, as reviewed in Sakane et al., 2007,
2008; Me´rida et al., 2008. Various DGKs regulate cell cycle
progression, apoptosis, migration, protein degradation, en-
docytosis, and protein trafficking from the endoplasmic
reticulum (ER) to the Golgi. Recently, it was shown that
DGK isoforms are involved in regulating the activation of Akt,
Ras, PKC, and mitogen-activated protein kinase (Olenchock
et al., 2006; Chibalin et al., 2008). DGKs are also known to
associate with receptor for activated C-kinase-1 (Imai et al.,
2009). Interestingly, many of those signaling pathways have
been shown to regulate melanogenesis (Hemesath et al.,
1998; Khaled et al., 2003; Park et al., 2004).
DAG exerts its effects by modulating the activity of a
number of enzymes, such as PKC, DGK, a- and b-chimerins,
Ras guanyl–releasing protein, and protein kinase D (Blumberg
et al., 2008). PKCb has been shown to induce melanogenesis
via the activation of tyrosinase (Park et al., 1993, 1999).
Moreover, when PKCb is activated, it binds receptor for
activated C-kinase-1 and translocates to the melanosome
membrane. The suppression of receptor for activated
C-kinase-1 by small interfering RNA (siRNA) decreases tyrosinase
activity (Park et al., 2004). These results demonstrate that
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PKCb is involved in the regulation of tyrosinase activity.
However, the role of PKC in melanogenesis remains con-
troversial. Previous reports demonstrated that pretreatment
with a PKC inhibitor or a high concentration of 12-O-
tetradecanoylphorbol 13-acetate, which downregulates spe-
cific isoforms of PKC including PKCa and PKCb, had no
significant effect on DAG-induced melanogenesis. These
findings suggest that DAG modulates melanogenesis via a
PKC-independent pathway (Carsberg et al., 1994).
DGK phosphorylates DAG to generate PA. DAG and PA
are second messengers, which are involved in several major
intracellular signal transduction pathways. PA has been
shown to activate a number of enzymes involved in signal
transduction, including PKCz, mammalian target of rapamy-
cin, Ras GTPase–activating protein, Raf-1 kinase, phosphati-
dylinositol-4-phosphate 5-kinase, and sphingosine kinase
(Sakane et al., 2007, 2008). Therefore, DGK is thought to
occupy a central position in signal transduction by control-
ling the balance between DAG and PA.
To assess the potential melanocyte-specific functions of
DGK isoforms, we examined the expression levels of DGK
isoforms in normal human epidermal melanocytes (NHEMs)
and in several melanoma cell lines. We also examined the
effects of DGK on melanogenesis using a DGK inhibitor
(R59949), siRNAs, and adenovirus-mediated overexpression
of DGK. We now report that DGK regulates melanogenesis
through modulation of the posttranslational processing of
tyrosinase.
RESULTS
Expression of DGK isoforms in melanocytic cells
We first examined the expression levels of the various DGK
isoforms in pigmented NHEMs, SK-Mel-23 human melanoma
cells, and B16F10 mouse melanoma cells using reverse
transcriptase–PCR (RT-PCR) (Figure 1a). DGKZ and DGKz
were the most abundant DGK isoforms expressed in NHEMs
and SK-Mel-23 cells, and DGKd was expressed at a moderate
level. In B16F10 murine melanoma cells, several other DGK
isoforms in addition to DGKZ and DGKz were also highly
expressed. We also confirmed the expression levels of DGK
isoforms using real-time RT-PCR (data not shown). As DGKZ
and DGKz were the most abundantly expressed isoforms in
all melanocytic cell lines examined, we focused our attention
on them. Two bands of DGKz were detected in 293A cells
(Figure 1b, arrowheads), which correspond to two splicing
variants, as previously reported (Ding et al., 1997). Interest-
ingly, the 130 kDa form is expressed at a higher level in
NHEMs and in B16F10 cells, whereas the smaller (115 kDa)
form predominates in SK-Mel-23 and 293A cells, suggesting
cell-specific expression of the two splicing variants.
Effect of a DGK inhibitor on melanin synthesis and tyrosinase
activity in NHEMs
To examine the effects of DGK on melanogenesis, we
measured the melanin content of NHEMs in the presence of
the DGK inhibitor, R59949. This inhibitor is known to inhibit
the activity of several DGK isoforms, such as DGKa (Jiang
et al., 2000), DGKd (Miele et al., 2007), and DGKz (Avila-
Flores et al., 2005), in a cell-specific manner. Recently, an
in vitro assay against a panel of protein kinases demonstrated
that R59949 is a specific inhibitor of DGK and does not affect
other protein kinases (Chibalin et al., 2008). NHEMs were
cultured with R59949 (1 or 2.5 mM) for 72 h, and at those
concentrations R59949 does not affect their proliferation
(Supplementary Figure S1 online). However, the melanin
content of NHEMs was significantly inhibited by treatment
with R59949 at 1 or 2.5 mM (Figure 1c).
To examine the mechanism(s) responsible for the de-
creased pigmentation induced by the DGK inhibitor, we
assayed tyrosinase activity by quantifying L-DOPA oxidation.
Consistent with the decrease in melanin content, tyrosinase
activity was significantly reduced by R59949 as early as
24 h (Figure 1d). Thus, inhibiting DGK decreases tyrosinase
activity, which subsequently decreases melanin synthesis in
NHEMs. To examine whether the inhibition of DGK also
regulates other melanogenesis-related proteins, NHEMs were
treated with R59949 at 1 or 2.5 mM for 24 and for 48 h. Protein
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Figure 1. Expression of diacylglycerol kinase (DGK) isoform mRNAs and
proteins in melanocytic cells, and effects of levels of tyrosinase and melanin.
(a) Expression levels of DGK isoform messenger RNAs examined by reverse
transcriptase–PCR. (b) Expression of DGKZ and DGKz examined by western
blot analysis using anti-DGK antibodies. Each lane represents lysates from
normal human epidermal melanocytes (NHEMs), SK-Mel-23 cells, B16F10
cells, and A293 cells; arrowheads indicate the bands of interest. (c) Melanin
content in NHEMs treated with the DGK inhibitor. Results are averages of
three independent experiments±SD. *Po0.05 compared with the control.
(d) NHEMs were cultured with 1–2.5 mM DGK inhibitor and tyrosinase
activity was examined; the results are averages of three independent
experiments±SD. **Po0.01 compared with the control at each time point.
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expression levels were then assessed by western blotting
(Figure 2a). The DGK inhibitor diminished tyrosinase expres-
sion, but had no effect on the levels of tyrosinase-related
protein-1 (TYRP1), DOPAchrome tautomerase, or Pmel17
proteins; note that microphthalmia-associated transcription
factor (MITF) levels at 48 h were slightly decreased.
We next examined MITF and tyrosinase messenger RNA
(mRNA) levels after treatment with the DGK inhibitor. MITF
and tyrosinase mRNA levels were not changed by treatment
with R59949 for 3–24 h (Figure 2b). These results show that
the DGK inhibitor does not decrease melanin synthesis by
downregulating MITF or tyrosinase mRNA levels, but instead
suggest that the regulation occurs at a posttranslational level.
Involvement of protein degradation in the DGK
inhibitor–induced reduction of tyrosinase
We next examined whether the DGK inhibitor–induced
reduction of tyrosinase was due to its proteolytic degradation.
We used two proteasome inhibitors, MG132 (a membrane
permeable proteasome inhibitor) and ALLN (a neutral cysteine
protease inhibitor that also blocks proteasome-mediated
proteolysis). The optimal concentration of each proteasome
inhibitor was determined previously (Ando et al., 2004).
Treatment with MG132 or ALLN did not rescue the DGK
inhibitor–reduced tyrosinase expression completely, but the
decrease of tyrosinase induced by R59949 could be partially
blocked by either inhibitor after co-incubation for 48 h
(Figure 3a).
Inhibition of DGK regulates the degradation of tyrosinase after
processing in the ER
The trafficking and stability of tyrosinase is modulated by its
glycosylation. Thus, glycosidase digestion was used to
evaluate whether the posttranslational processing of tyrosi-
nase is disrupted in DGK inhibitor–treated melanocytic cells.
EndoH cleaves tyrosinase with early high mannose when it is
immature in the ER, but does not affect mature forms of
tyrosinase containing complex carbohydrates once it has
been processed through the Golgi (Ando et al., 2006).
Although the total amount of tyrosinase protein was decreased
by treatment with R59949, the inhibitor did not affect the
amount of EndoH-sensitive tyrosinase in B16F10 cells or in
NHEMs (Figure 3b), showing that it had no effect of de novo
synthesis of tyrosinase or its early processing.
Inhibition of DGK diminishes the induction of melanogenesis by
aMSH
To investigate the possible effect of the DGK inhibitor on
cAMP-induced melanogenesis, we treated B16F10 melano-
ma cells with a-melanocyte-stimulating hormone (aMSH)
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Figure 2. Effect of the diacylglycerol kinase (DGK) inhibitor on melanogenesis and on the expression of melanocyte-specific factors in normal human
epidermal melanocytes. Melanogenesis-related proteins were analyzed by western blot (a) and real-time reverse transcriptase–PCR analysis (b) to characterize
tyrosinase and microphthalmia-associated transcription factor (MITF) messenger RNA levels in DGK inhibitor–treated cells. Results are averages of three
independent experiments±SD. DCT, DOPAchrome tautomerase; TYRP1, tyrosinase-related protein-1.
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(100 nM) in the presence or absence of R59949 (10–20mM)
and then measured melanin content and tyrosinase protein
levels. As expected, melanin content was dramatically
increased by aMSH treatment alone. However, melanin
content was greatly reduced in cells treated with aMSH in the
presence of 20 mM R59949 (Figure 3c). Treatment of B16F10
cells with aMSH also increased the levels of tyrosinase
protein (Figure 3d), but pretreatment with the DGK inhibitor
diminished the level of tyrosinase protein and blocked the
aMSH-induced increase in tyrosinase level. These results
indicate that the inhibition of DGK affects cAMP-induced
pigmentation and has a potent effect to reduce melanin
through its effects on tyrosinase.
Effect of PD98059 and Go¨6983 on tyrosinase levels
Some DGK isoforms are known to be involved in the
extracellular signal–regulated kinase (ERK) or PKC signaling
pathways. To investigate whether the ERK and/or the PKC
signaling pathways could interfere with the DGK inhibitor–-
induced reduction of tyrosinase, we examined tyrosinase
protein levels in the presence of R59949 and PD98059, a
selective inhibitor of MEK (mitogen-activated protein/ERK
kinase, a specific upstream activator of ERK) or Go¨6983 (a
PKC inhibitor). NHEMs were treated with R59949 for 24 h in
the absence or presence of PD98059 or Go¨6983 (added 1 h
before addition of the DGK inhibitor). Neither of those
inhibitors abrogated the DGK inhibitor–induced reduction of
tyrosinase (Figure 3e), which suggests that another signaling
pathway could be involved in the DGK inhibitor–induced
reduction of tyrosinase.
Effects of DGK silencing on melanogenesis
Treatment with the DGK inhibitor was effective in reducing
melanogenesis, but as noted above R59949 is not a DGK
isoform–specific inhibitor (Sakane et al., 2008). To determine
which DGK isoform(s) is involved in the DGK inhibitor–induced
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Figure 3. Effect of the diacylglycerol kinase (DGK) inhibitor on the posttranslational processing of tyrosinase and proteasomal degradation. (a) Levels of
tyrosinase in B16F10 cells after treatment with the DGK inhibitor (20mM) for 48 h in the presence or absence of proteasome or lysosomal protease inhibitors
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reduction of melanogenesis, we used isoform-specific
siRNAs to inhibit the activity of each DGK isoform. First,
we examined whether R59949 affects melanin content,
tyrosinase activity, and/or tyrosinase expression in SK-Mel-23
melanoma cells, which are much easier to transfect than
NHEMs. As expected, melanin content, tyrosinase activity,
and protein levels were all reduced by the DGK inhibitor
(Supplementary Figure S2 online), which is consistent with its
effects on NHEMs. SK-Mel-23 cells were then transiently
transfected with siRNAs for DGKZ and DGKz, or with a
control nonspecific siRNA. These experiments were per-
formed using two different DGK isoform–specific duplexes for
each isoform. We examined the expression of DGK isoforms
using real-time RT-PCR 48h after transfection. The results of
that analysis confirmed that the mRNA level of each DGK
isoform was significantly reduced in cells transfected with the
DGK siRNA (Figure 4a, left), and western blotting confirmed
the decreased protein level of each isoform (Figure 4a, right).
We observed a reduction of tyrosinase protein level 4 days
after transfection with the DGKZ or DGKz siRNAs, but there
was no significant effect of those two DGK isoforms on MITF
protein levels (Figure 4b). To confirm the functional role
of DGKZ and DGKz in regulating melanin synthesis, we
assayed melanin content 6 days after the initial transfection
of siRNA, because it takes a longer time to reduce melanin
content once tyrosinase activity is decreased. Melanin
content was dramatically reduced only by the two DGKz
siRNAs, and not by the DGKZ siRNAs (Figure 4c). DGKZ
siRNA also reduced tyrosinase expression, but the effect was
slight compared with the DGKz siRNA. These data show that
DGKz is specifically involved in the regulation of melano-
genesis.
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Figure 4. Effect of the diacylglycerol kinase (DGK) inhibition on melanogenesis in SK-Mel-23 cells. (a) Efficiency of small interfering RNAs (siRNAs)
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Adenovirus-mediated overexpression of DGKf increases
tyrosinase protein levels
To further characterize the role of DGKz in modulating tyrosi-
nase function, we examined whether the overexpression of
DGKz affects tyrosinase expression in NHEMs. NHEMs were
transduced with 25 or 50 multiplicity of infection of adenovirus-
expressing DGKa or DGKz (Ad-DGKs) for 24h. Cells received
fresh medium and were then further incubated for 3 days.
Western blot analysis was then performed to confirm the
adenovirus-mediated expression of DGKs. Protein levels of
DGKa or DGKz increased in dose-dependent manners
(Supplementary Figure S3 online). On the basis of these
results, NHEMs were used for the following experiments 72h
after transduction with 25 or 50 multiplicity of infection Ad-
DGKs. Consistently, the adenovirus-mediated overexpression
of DGKz was the only DGK isoform that increased tyrosinase
protein levels in NHEMs (and MITF to some extent) (Figure 5a),
but without a substantial increase of tyrosinase mRNA levels
(Figure 5b). On the basis of these results, we conclude that
DGKz regulates tyrosinase at the posttranscriptional level.
DISCUSSION
DGKs contribute to diverse activities in various tissues and
cells (Sakane et al., 2007, 2008). DAG is known to regulate
melanogenic functions in PKC-dependent and -independent
manners (Gordon and Gilchrest, 1989; Park et al., 1993,
1999, 2004; Carsberg et al., 1994, 1995; Allan et al., 1995).
In this study, we investigated the effects of DGKs on
melanogenesis in NHEMs and in melanoma cell lines. First,
we demonstrate that inhibition of DGK activity reduces
melanin content in NHEMs at a concentration where it has no
effect on cell number or cell viability. The inhibition of DGK
reduced the levels of tyrosinase protein and melanin content
in all melanocytic cell lines examined. One difference
between the cell lines is that melanoma cell lines (B16F10
and SK-Mel-23) are much less sensitive to R59949 than are
NHEMs, and require higher concentrations to reduce levels
of melanin content and tyrosinase compared with NHEMs
(10–20 mM vs. 1–2.5 mM).
Our results with glycosidase digestion by EndoH reveal
that a posttranscriptionally mediated decrease in mature
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tyrosinase protein accounts for the DGK inhibitor–elicited
reduction in tyrosinase activity. As shown in Figure 5c, our
model suggests that the DGK inhibitor treatment disrupts the
amount of mature tyrosinase that reaches melanosomes,
which results in a dramatic decrease of functional tyrosinase
and melanin synthesis. The decrease of tyrosinase protein
levels induced by the DGK inhibitor could be blocked
slightly by proteasome inhibitors, which suggests that it
reduces melanin synthesis by accelerating the degradation of
tyrosinase.
Levels of proteins are regulated by a balance between their
synthesis and degradation. The maturation of tyrosinase is
inefficient, with only B50% of protein passing the quality
control test and reaching its mature form under optimal
conditions (Halaban et al., 1997). As the DGK inhibitor did
not reduce MITF or tyrosinase mRNAs, and reduced only the
mature form of tyrosinase, the DGK inhibitor–induced
decrease of tyrosinase is a posttranscriptionally mediated
decrease in the mature form of tyrosinase, which is involved
with the protein degradation machinery. However, little
attention has been paid to regulating tyrosinase degradation,
which depends on tyrosinase processing and maturation in
the ER and Golgi, and its degradation via the ubiquitin
proteasome system and/or the endosomal/lysosomal system
(Ando et al., 2007). Tyrosinase destined for degradation in the
ER is proteolyzed by proteasomes via ER-associated protein
degradation. Fatty acids (Ando et al., 2004, 2006), phospho-
lipase D2 (Kageyama et al., 2004), and p38 (Bellei et al.,
2010) are known to accelerate the degradation of tyrosinase
by increasing the proteasomal degradation of tyrosinase.
In addition, tyrosinase degradation also occurs following
its complete maturation in the Golgi. In fact, tyrosinase
processed beyond the post-Golgi stage can be rapidly
degraded by integration into ER-associated protein degrada-
tion, as observed in linoleic acid–treated melanoma cells
(Ando et al., 2006), or by the endosomal/lysosomal system, as
observed in phenylthiourea-treated melanoma cells (Hall and
Orlow, 2005).
The retention of tyrosinase in the ER/Golgi also occurs for
mutant forms of tyrosinase and TYRP1 that cause types I and
3 oculocutaneous albinism, respectively, (Halaban et al.,
2000; Toyofuku et al., 2001) and in human amelanotic
melanoma cells (Halaban et al., 1997). The sum of those
studies suggests that tyrosinase degradation is an effective
and physiological way of regulating melanogenesis. Interest-
ingly, fatty acids are known to regulate the growth
factor–induced activation of DGKs in vascular smooth muscle
cells (Du et al., 2001). DGKa is the major DGK isoform in
vascular smooth muscle, and growth factors increase DGKa
activity. Fatty acids inhibit the DGK activity induced by the
growth factors. On the other hand, the DGK inhibitor
increases DAG levels, and the accumulation of DAG
increases PKC activity (Chibalin et al., 2008). PKCa is known
to enhance phospholipase D activity in human melanoma
cells (Oka et al., 2003). PKC inhibitors increase melanin
content and tyrosinase protein levels in B16F10 cells.
Overexpression of PKCa prevents basal and forskolin-induced
tyrosinase promoter activity in B16F10 cells (Bertolotto et al.,
1998). Therefore, DGK might act as a downstream signal
for fatty acids, or as an upstream signal for phospholipase
D, regulating melanogenesis through the degradation of
tyrosinase.
The presence of PKCa and absence of PKCb in melanoma
cell lines, including B16 and SK-Mel-23, has been reported
(Oka and Kikkawa, 2005). Therefore, differences in the
expression of PKC isoforms could be one reason for different
responses between cell lines. Further, DGKz/ cells demo-
nstrated impaired recruitment of PKCb to the membrane
(Olenchock et al., 2006). PKCb is known to be involved in
regulating melanogenesis in NHEMs, and therefore DGK
might function in part by regulating the activity of PKCb.
To examine the isoform-specific effect of DGK in melano-
genesis, we used siRNAs to inhibit DGK activity. We found
that the knockdown of DGKz decreased melanin content and
levels of tyrosinase protein in SK-Mel-23 cells. To character-
ize the role of DGKs in modulating tyrosinase levels, we
examined whether the overexpression of DGKz affects
tyrosinase levels in NHEMs. Interestingly, the adenovirus-
mediated overexpression of DGKz increased levels of
tyrosinase protein in NHEMs, but did not affect tyrosinase
mRNA levels. On the basis of these results, we speculate that
DGKz regulates tyrosinase function at the protein level. As
DGK does not regulate the expression of tyrosinase directly,
the increase of tyrosinase protein associated with over-
expression of DGKz appears to be due to inhibition of
tyrosinase degradation. In addition, we examined whether
the overexpression of DGKz rescues the DGK inhibitor–
induced decrease of tyrosinase in NHEMs. However,
overexpression of DGKz did not rescue the DGK inhibitor–
induced decrease of tyrosinase. These data suggest that not
only DGKz but also other DGK isoform(s) may be involved in
the DGK inhibitor–induced decrease of tyrosinase.
It has been demonstrated that DAG and PA are lipids with
important functions in membrane trafficking (Roth, 1999;
Haucke and Di, 2007). DAG binds to and activates various
proteins needed for vesicle formation, such as protein kinase
D, ADP-ribosylation factor, and GTPase-activating protein
(Roth, 1999; Haucke and Di, 2007). PA can also bind to and
activate enzymes, such as coatomer, ADP-ribosylation factor,
and kinesin (Manifava et al., 2001). It has also been
demonstrated that DGKd suppresses ER to Golgi trafficking
(Nagaya et al., 2002), and DGKd is also involved in
endocytosis through its binding to adaptor protein 2a
(Pelkmans et al., 2005; Kawasaki et al., 2008). In addition,
DGKz is known to interact with several PDZ (postsynaptic
density protein, disc-large, and zonula occludens-1)-contain-
ing proteins, including syntrophin, PSD-95, and sorting nexin
27 (Kim et al., 2010). Functionally, DGKz overexpression
increases spine density in cultured neurons in a manner that
requires DGK catalytic activity and PSD-95 binding. Con-
versely, knockdown of DGKz in cultured neurons decreases
spine density, an effect that is rescued by co-expression of
wild-type DGKz, but not by a DGKz mutant that lacks
catalytic activity or PSD-95 binding (Kim et al., 2010).
Therefore, DGK activity is thought to be necessary for the
interaction between DGK and other proteins. In melanocytes,
www.jidonline.org 2797
M Kawaguchi et al.
DGK Regulates Tyrosinase Expression
the PDZ domain protein GIPC is known to interact with
TYRP1 in the Golgi region, and it was proposed that
this interaction is involved in the trafficking of TYRP1 along
the endosomal pathway (Kedlaya et al., 2011). The identifi-
cation of target molecules for DGK would allow us to more
fully understand the detailed machinery that regulates
melanogenesis.
In summary, we demonstrate that DGK is involved in the
regulation of melanogenesis through the modulation of
tyrosinase protein levels, which is regulated by the
protein degradation machinery. The DGKz isoform is clearly
involved in that process, and it remains possible that other
DGK isoforms might also have a role. Our study sheds new
light on the dynamic regulation of tyrosinase and provides
additional evidence on the important role of DGK in
posttranslational processing of tyrosinase in melanocytes.
MATERIALS AND METHODS
Chemicals and antibodies used
R59949, PD98059, Go¨6983, MG-132, ALLN, and aMSH were from
Calbiochem (San Diego, CA), and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, synthetic melanin, and L-DOPA were
from Sigma Aldrich (St Louis, MO).
DGKa and DGKZ antibodies were from ProteinTech (Chicago,
IL). The DGKz (N-19) antibody was from Santa Cruz Biotech (Santa
Cruz, CA), the MITF antibody (C5) was from Thermo Scientific
(Fremont, CA) and the b-actin antibody was from Abcam (Cambridge,
MA). Antibodies to tyrosinase (aPEP7h and aPEP7), TYRP1 (aPEP1h),
DOPAchrome tautomerase (aPEP8h), and Pmel17 (aPEP13h) were
from our own laboratory (Virador et al., 2001).
Cell culture
Lightly pigmented NHEMs were obtained from Cascade Biologics
(Portland, OR) and were cultured in melanocyte growth medium
consisting of Medium 254 and human melanocyte growth supple-
ment (Cascade Biologics) with 1% Penicillin/Streptomycin (Invitro-
gen, Carlsbad, CA) in a humidified atmosphere containing 5% CO2
in air at 37 1C. NHEMs from the third to seventh passages were used
in these experiments. B16F10 mouse melanoma cells and SK-Mel-23
human–pigmented melanoma cells were cultured in DMEM supple-
mented with 10% fetal bovine serum and 1% PenicillinStreptomycin
(Invitrogen). The medium was changed every second day. 293A
cells (Invitrogen) were cultured according to the manufacturer’s
instructions.
PCR primers
Pre-designed primer sets used in this study are listed in the
Supplementary Information online.
RNA extraction, RT-PCR, and real-time quantitative RT-PCR
Details of the RNA extraction and real-time RT-PCR procedures, and
data analysis are listed in the Supplementary Methods online.
Glycosidase digestion
Cell extracts (5 mg protein) were digested with 1,000U EndoH (New
England Biolabs, Beverly, MA) for 3 h at 37 1C. After the digestion,
cell extracts were mixed with Tris-glycine SDS sample buffer
(Invitrogen) supplemented with 2-mercaptoethanol and were boiled
for 5min. Samples were subjected to SDS-PAGE, and immuno-
reactive bands were detected by western blotting using the aPEP7 or
aPEP7h antibodies.
Western blotting analysis
Details of the western blotting analysis are provided in the
Supplementary Methods online.
Melanin content and tyrosinase assays
Details of these assays are provided in the Supplementary Methods
online.
Targeted inhibition using siRNA
Details of the siRNA procedures are listed in the Supplementary
Methods online.
Recombinant adenoviral vector construction and infection
Details of the lentiviral vectors used and infection procedures are
provided in the Supplementary Methods online.
Statistical analysis
The results were averaged over three or four independent experi-
ments. P-values were calculated using Student’s t-test, and a Po0.05
is considered significant.
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